Condition (MeSH)
Simian Acquired Immunodeficiency Syndrome
ClinicalTrials.gov lists 1 trial for Simian Acquired Immunodeficiency Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
5 sections measured, none recorded · 1 not measured yet · 1 not computed
1 of the 1 trial is tagged with Simian Acquired Immunodeficiency Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Simian Acquired Immunodeficiency Syndrome trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2014 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Simian Acquired Immunodeficiency Syndrome trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Observational | 1 |
How many Simian Acquired Immunodeficiency Syndrome trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Simian Acquired Immunodeficiency Syndrome? (57)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. | Frontiers in immunology | 2021 | Yes |
| CD24Fc protects against viral pneumonia in simian immunodeficiency virus-infected Chinese rhesus monkeys. | Cellular & molecular immunology | 2020 | Yes |
| CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS. | Antiviral research | 2018 | Yes |
| Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes. | PLoS pathogens | 2018 | Yes |
| Early antibody therapy can induce long-lasting immunity to SHIV. | Nature | 2017 | Yes |
Showing 5 of 57 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.